Das ist die Zukunft! - 500 Beiträge pro Seite
eröffnet am 28.11.17 19:55:48 von
neuester Beitrag 04.02.21 12:10:37 von
neuester Beitrag 04.02.21 12:10:37 von
Beiträge: 9
ID: 1.268.288
ID: 1.268.288
Aufrufe heute: 0
Gesamt: 1.793
Gesamt: 1.793
Aktive User: 0
ISIN: US13764M2098 · WKN: A3DK5G · Symbol: CNBX
0,0120
USD
-3,04 %
-0,0004 USD
Letzter Kurs 02:10:00 Nasdaq OTC
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8300 | +161,43 | |
| 3,0920 | +22,21 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 15,550 | -17,02 | |
| 9,7200 | -19,60 | |
| 0,9250 | -23,55 | |
| 14,510 | -32,32 | |
| 8,0000 | -36,76 |
Feedback
Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) is engaged within the research, development, and commercialization of cannabis-based pharmaceuticals to treat a wide range of ailments. Shares of the cannabis pharmaceutical developer are rallying 17.89%, through early trading on Tuesday, November 28, 2017. Over the past month, Cannabics Pharmaceuticals, Inc. has seen average daily volume of 274,162 shares. However, volume of 685,563 shares or dollar volume of $774,686, has already exchanged hands on the day.
Shares of Cannabics Pharmaceuticals, Inc. are rallying today, after the company announced that it has received a new license from the Israeli Ministry of Health to test CBD compounds within the treatment of tumors. The research license gives the company a wide range of capabilities to begin testing and research. Here is the full press release detailing of the research license:
Cannabics Pharmaceuticals, Inc. Press Release:
TEL-AVIV, Israel, Nov. 28, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids.
The new license will enable the company to continue our vision of developing an ecosystem for creation of diagnostic tools and bringing to the market diagnostic services for cancer patients who are medicated with cannabis. Our forward looking plan encompasses a synergy between HTS (High Throughput Screening), CTCs (Circulating Tumor Cells), Drug Efficacy, and Genomic Data to provide therapists and their patients with personalized supportive data for their treatment.
About Cannabics Pharmaceuticals, Inc.
Cannabics Pharmaceuticals, Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Quelle: http://emerginggrowth.com/cannabics-pharmaceuticals-inc-otcq…
Shares of Cannabics Pharmaceuticals, Inc. are rallying today, after the company announced that it has received a new license from the Israeli Ministry of Health to test CBD compounds within the treatment of tumors. The research license gives the company a wide range of capabilities to begin testing and research. Here is the full press release detailing of the research license:
Cannabics Pharmaceuticals, Inc. Press Release:
TEL-AVIV, Israel, Nov. 28, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids.
The new license will enable the company to continue our vision of developing an ecosystem for creation of diagnostic tools and bringing to the market diagnostic services for cancer patients who are medicated with cannabis. Our forward looking plan encompasses a synergy between HTS (High Throughput Screening), CTCs (Circulating Tumor Cells), Drug Efficacy, and Genomic Data to provide therapists and their patients with personalized supportive data for their treatment.
About Cannabics Pharmaceuticals, Inc.
Cannabics Pharmaceuticals, Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Quelle: http://emerginggrowth.com/cannabics-pharmaceuticals-inc-otcq…
Schaut doch gut aus.
Antwort auf Beitrag Nr.: 56.571.541 von herku am 29.12.17 22:16:14Ich hoffe hier sind alle bis jetzt zufrieden?
Gute News: Klinische Studien mit positiven Ergebnissen abgeschlossen im Bereich Anti-Tumor. http://cannabics.com/investors/
Trading Spotlight
!
Dieser Beitrag wurde von SelfMODus moderiert. Grund: Das Posting wird auf Wunsch des Users gelöscht.
#hold 😎
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| -3,26 | |
| -33,33 | |
| 0,00 | |
| -4,55 | |
| 0,00 | |
| 0,00 | |
| -0,70 | |
| -0,49 | |
| -2,97 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 204 | ||
| 190 | ||
| 146 | ||
| 69 | ||
| 32 | ||
| 29 | ||
| 29 | ||
| 26 | ||
| 26 | ||
| 25 |
